{
    "ticker": "RGLS",
    "name": "Regulus Therapeutics Inc.",
    "description": "Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines based on the modulation of microRNAs, a class of RNA molecules that play a crucial role in gene expression and regulation. Founded in 2007, Regulus is at the forefront of advancing the understanding of microRNA biology and its potential therapeutic applications in various diseases, including kidney disease, liver disease, and cancer. The company's unique platform enables the development of targeted therapies that can address unmet medical needs and improve patient outcomes. Regulus has several programs in its pipeline, with promising candidates designed to treat conditions such as autosomal dominant polycystic kidney disease (ADPKD) and other serious diseases. The company's commitment to scientific excellence and collaboration with leading research institutions has positioned it as a key player in the biopharmaceutical industry. With a focus on innovation and patient-centric solutions, Regulus Therapeutics aims to deliver transformative therapies that harness the power of microRNA modulation.",
    "industry": [
        "Biopharmaceuticals",
        "Therapeutics"
    ],
    "headquarters": "La Jolla, California, USA",
    "founded": "2007",
    "website": "https://www.regulustherapeutics.com",
    "ceo": "Jay L. Hagan",
    "social_media": {
        "twitter": "https://twitter.com/regulustx",
        "linkedin": "https://www.linkedin.com/company/regulus-therapeutics/"
    },
    "investor_relations": "https://ir.regulustherapeutics.com",
    "key_executives": [
        {
            "name": "Jay L. Hagan",
            "position": "CEO"
        },
        {
            "name": "Richard J. Hargreaves",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Clinical Programs",
            "products": [
                "RG-012",
                "RG-101"
            ]
        }
    ],
    "seo": {
        "meta_title": "Regulus Therapeutics Inc. | Innovative MicroRNA Medicines",
        "meta_description": "Explore Regulus Therapeutics Inc., a leader in microRNA therapeutics. Discover our innovative pipeline and commitment to advancing healthcare.",
        "keywords": [
            "Regulus Therapeutics",
            "microRNA",
            "biopharmaceuticals",
            "therapeutics",
            "kidney disease",
            "liver disease",
            "cancer"
        ]
    },
    "faq": [
        {
            "question": "What is Regulus Therapeutics known for?",
            "answer": "Regulus Therapeutics is known for developing innovative medicines based on microRNA modulation."
        },
        {
            "question": "Who is the CEO of Regulus Therapeutics?",
            "answer": "Jay L. Hagan is the CEO of Regulus Therapeutics Inc."
        },
        {
            "question": "Where is Regulus Therapeutics headquartered?",
            "answer": "Regulus Therapeutics is headquartered in La Jolla, California, USA."
        },
        {
            "question": "What are Regulus Therapeutics' main products?",
            "answer": "Regulus Therapeutics is focused on clinical programs like RG-012 and RG-101."
        },
        {
            "question": "When was Regulus Therapeutics founded?",
            "answer": "Regulus Therapeutics was founded in 2007."
        }
    ],
    "competitors": [
        "ARNA",
        "SRNE",
        "MDGL",
        "CRSP"
    ],
    "related_stocks": [
        "BMY",
        "GILD",
        "AMGN",
        "ABBV"
    ]
}